Y0000626
氨丁三醇
European Pharmacopoeia (EP) Reference Standard
别名:
酮咯酸 三羟甲基氨基甲烷盐, 托拉多尔, （±）-5-苄基-2,3-二氢-1H-吡咯嗪-1羧酸 三羟甲基氨基甲烷盐
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C15H13NO3 · C4H11NO3
化学文摘社编号:
分子量:
376.40
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
pharmaceutical primary standard
API类
ketorolac
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
NC(CO)(CO)CO.OC(=O)C1CCn2c1ccc2C(=O)c3ccccc3
InChI
1S/C15H13NO3.C4H11NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13;5-4(1-6,2-7)3-8/h1-7,11H,8-9H2,(H,18,19);6-8H,1-3,5H2
InChI key
BWHLPLXXIDYSNW-UHFFFAOYSA-N
基因信息
human ... PTGS1(5742), PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Ketorolac trometamol for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
警示用语：
Danger
危险分类
Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
靶器官
Respiratory system
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
Meizi Wang et al.
Retina (Philadelphia, Pa.), 32(10), 2158-2164 (2012-10-27)
To investigate the concentrations and pharmacokinetics of ketorolac in the rabbits by three different routes of administrations: a single intracameral, intravitreal, and suprachoroidal injection. Fifty-four New Zealand white rabbits received ketorolac (250 μg/0.05 mL) in one eye by a single
Andy He et al.
Current medical research and opinion, 28(12), 1873-1880 (2012-10-27)
An intranasal (IN) formulation of ketorolac was recently FDA approved in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The aim of this paper is to provide an overview
Mrinal Kanti Bain et al.
International journal of biological macromolecules, 50(3), 565-572 (2012-02-04)
The effect of molecular weight of poly(vinyl alcohol) (PVA) and sodium chloride on the gelation temperature of methylcellulose (MC) was studied with the objective to develop a MC based formulation for sustained delivery of ketorolac tromethamine a model ophthalmic drug.
Henry D Perry et al.
Expert opinion on pharmacotherapy, 7(1), 99-107 (2005-12-24)
Ketorolac tromethamine 0.4% ophthalmic solution, a recent reformulation of the original ketorolac tromethamine 0.5% solution, is indicated for the reduction of ocular pain and burning/stinging following cataract and refractive surgery. Studies have demonstrated that ketorolac tromethamine 0.4% has equivalent efficacy
David R Drover et al.
Anesthesia and analgesia, 114(6), 1270-1276 (2012-04-03)
Ketorolac tromethamine (ketorolac) administration reduces postoperative opioid requirements. The pharmacokinetic characteristics of intranasal ketorolac tromethamine in children have not been characterized. Our objective of this study was to determine the pharmacokinetics of a single intranasal dose of ketorolac in adolescent
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持